- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT06609239
Długoterminowa ocena bezpieczeństwa i skuteczności Lunsekimig (SAR443765) u dorosłych pacjentów chorych na astmę o umiarkowanym lub ciężkim przebiegu. (AIRPHRODITE)
Otwarte badanie rozszerzone mające na celu ocenę długoterminowego bezpieczeństwa i skuteczności podskórnego lunsekimigu u dorosłych uczestników chorych na astmę o umiarkowanym lub ciężkim przebiegu, którzy uczestniczyli w badaniu DRI16762
This is a phase 2, open-label extension study to evaluate the long-term safety and efficacy of lunsekimig in adult participants with asthma who have previously completed the parent studies. After completion of the parent study, eligible participants will be offered the opportunity to participate in the long-term extension (LTE) study with lunsekimig.
The study duration will be up to 148 weeks with a treatment duration being up to 144 weeks.
Przegląd badań
Typ studiów
Zapisy (Szacowany)
Faza
- Faza 2
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Benoni, Afryka Południowa, 1500
- Investigational Site Number : 7100004
-
Benoni, Afryka Południowa, 1500
- Investigational Site Number : 7100005
-
Cape Town, Afryka Południowa, 7530
- Investigational Site Number : 7100003
-
Cape Town, Afryka Południowa, 7700
- Investigational Site Number : 7100002
-
Durban, Afryka Południowa, 4001
- Investigational Site Number : 7100001
-
Pretoria, Afryka Południowa, 0157
- Investigational Site Number : 7100006
-
-
-
-
-
Buenos Aires, Argentyna, 1121
- Investigational Site Number : 0320005
-
Buenos Aires, Argentyna, 1414
- Investigational Site Number : 0320004
-
Buenos Aires, Argentyna, 1425
- Investigational Site Number : 0320001
-
Buenos Aires, Argentyna, 1122
- Investigational Site Number : 0320012
-
Buenos Aires, Argentyna, 1425
- Investigational Site Number : 0320011
-
La Plata, Buenos Aires, Argentyna, B1904CUL
- Investigational Site Number : 0320003
-
Mendoza, Argentyna, 5500
- Investigational Site Number : 0320009
-
Mendoza, Argentyna, 5500
- Investigational Site Number : 0320015
-
Santa Fe, Argentyna, 3000
- Investigational Site Number : 0320010
-
-
Buenos Aires
-
Berazategui, Buenos Aires, Argentyna, 1886
- Investigational Site Number : 0320007
-
Lobos, Buenos Aires, Argentyna, 7240
- Investigational Site Number : 0320013
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentyna, 2000
- Investigational Site Number : 0320002
-
Rosario, Santa Fe Province, Argentyna, 2000
- Investigational Site Number : 0320006
-
Rosario, Santa Fe Province, Argentyna, 2000
- Investigational Site Number : 0320020
-
-
Tucumán Province
-
San Miguel de Tucumán, Tucumán Province, Argentyna, 4000
- Investigational Site Number : 0320008
-
-
-
-
-
Rio de Janeiro, Brazylia, 22241-180
- CCBR / IBPClin - Instituto Brasil de Pesquisa Clínica- Site Number : 0760006
-
São Paulo, Brazylia, 05403-000
- Incor - Instituto do Coracao- Site Number : 0760011
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brazylia, 40060-330
- Associacao Proar- Site Number : 0760003
-
-
Goiás
-
Goiânia, Goiás, Brazylia, 74605-020
- Universidade Federal de Goias- Site Number : 0760007
-
-
Paraná
-
Curitiba, Paraná, Brazylia, 80030-110
- CETI - Centro de Estudos em Terapias Inovadoras- Site Number : 0760002
-
-
Pernambuco
-
Recife, Pernambuco, Brazylia, 50070-550
- Instituto de Medicina Integral Professor Fernando Figueira- Site Number : 0760009
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brazylia, 90610-000
- Hospital São Lucas da PUCRS - Porto Alegre - Avenida Ipiranga- Site Number : 0760001
-
-
Santa Catarina
-
Blumenau, Santa Catarina, Brazylia, 89030-101
- Hospital Dia do Pulmão- Site Number : 0760005
-
-
-
-
Biobio
-
Concepción, Biobio, Chile, 4070094
- Investigational Site Number : 1520013
-
-
Maule Region
-
Talca, Maule Region, Chile, 3465584
- Investigational Site Number : 1520001
-
-
Reg Metropolitana de Santiago
-
Recoleta, Reg Metropolitana de Santiago, Chile, 8420000
- Investigational Site Number : 1520015
-
Santiago, Reg Metropolitana de Santiago, Chile, 7500587
- Investigational Site Number : 1520006
-
Santiago, Reg Metropolitana de Santiago, Chile, 7500692
- Investigational Site Number : 1520005
-
Santiago, Reg Metropolitana de Santiago, Chile, 7500698
- Investigational Site Number : 1520004
-
Santiago, Reg Metropolitana de Santiago, Chile, 7750495
- Investigational Site Number : 1520002
-
-
Valparaiso
-
Quillota, Valparaiso, Chile, 2260877
- Investigational Site Number : 1520008
-
Viña del Mar, Valparaiso, Chile, 2531172
- Investigational Site Number : 1520011
-
Viña del Mar, Valparaiso, Chile, 2540364
- Investigational Site Number : 1520012
-
-
-
-
-
Beijing, Chiny, 100144
- Investigational Site Number : 1560011
-
Changchun, Chiny, 130021
- Investigational Site Number : 1560010
-
Changsha, Chiny, 410015
- Investigational Site Number : 1560017
-
Chengde, Chiny, 067020
- Investigational Site Number : 1560021
-
Guangzhou, Chiny, 510150
- Investigational Site Number : 1560009
-
Guangzhou, Chiny, 510000
- Investigational Site Number : 1560053
-
Guangzhou, Chiny, 510163
- Investigational Site Number : 1560001
-
Guiyang, Chiny, 550002
- Investigational Site Number : 1560037
-
Hefei, Chiny, 230032
- Investigational Site Number : 1560006
-
Hohhot, Chiny, 010050
- Investigational Site Number : 1560014
-
Lanzhou, Chiny, 730000
- Investigational Site Number : 1560030
-
Nanchang, Chiny, 330006
- Investigational Site Number : 1560007
-
Pingxiang, Chiny, 337055
- Investigational Site Number : 1560002
-
Shanghai, Chiny, 200433
- Investigational Site Number : 1560013
-
Shenyang, Chiny, 110004
- Investigational Site Number : 1560015
-
Taiyuan, Chiny, 030001
- Investigational Site Number : 1560057
-
Tianjin, Chiny, 300211
- Investigational Site Number : 1560055
-
Wenzhou, Chiny, 325027
- Investigational Site Number : 1560005
-
Wuhan, Chiny, 430030
- Investigational Site Number : 1560003
-
Wuhan, Chiny, 430030
- Investigational Site Number : 1560022
-
Xuzhou, Chiny, 221006
- Investigational Site Number : 1560004
-
Yangzhou, Chiny, 225000
- Investigational Site Number : 1560016
-
Zhanjiang, Chiny, 524004
- Investigational Site Number : 1560012
-
-
-
-
-
Madrid, Hiszpania, 28007
- Investigational Site Number : 7240008
-
Madrid, Hiszpania, 28010
- Investigational Site Number : 7240011
-
-
Catalunya [Cataluña]
-
Barcelona, Catalunya [Cataluña], Hiszpania, 08017
- Investigational Site Number : 7240009
-
-
-
-
-
Calicut, Indie, 673008
- Investigational Site Number : 3560007
-
Hyderabad, Indie, 500084
- Investigational Site Number : 3560009
-
Kanpur, Indie, 208001
- Investigational Site Number : 3560008
-
Nagpur, Indie, 441203
- Investigational Site Number : 3560001
-
Pune, Indie, 411057
- Investigational Site Number : 3560004
-
-
-
-
-
Ashkelon, Izrael, 7830604
- Investigational Site Number : 3760006
-
Haifa, Izrael, 3104802
- Investigational Site Number : 3760001
-
Haifa, Izrael, 3436212
- Investigational Site Number : 3760008
-
Jerusalem, Izrael, 9103102
- Investigational Site Number : 3760003
-
Jerusalem, Izrael, 9112001
- Investigational Site Number : 3760002
-
Petah Tikva, Izrael, 4941492
- Investigational Site Number : 3760010
-
Rehovot, Izrael, 7610001
- Investigational Site Number : 3760004
-
Tel Aviv, Izrael, 6423906
- Investigational Site Number : 3760007
-
-
-
-
-
Fukushima, Japonia, 960-1295
- Investigational Site Number : 3920008
-
Kyoto, Japonia, 610-0113
- Investigational Site Number : 3920006
-
Kyoto, Japonia, 612-8555
- Investigational Site Number : 3920009
-
Miyazaki, Japonia, 889-1692
- Investigational Site Number : 3920012
-
-
Kagawa-ken
-
Sakaidechō, Kagawa-ken, Japonia, 762-8550
- Investigational Site Number : 3920002
-
-
Tokyo
-
Chūō, Tokyo, Japonia, 104-0031
- Investigational Site Number : 3920011
-
-
Yamaguchi
-
Ube, Yamaguchi, Japonia, 755-8505
- Investigational Site Number : 3920005
-
-
-
-
Ontario
-
Ajax, Ontario, Kanada, L1S 2J5
- Investigational Site Number : 1240013
-
Hamilton, Ontario, Kanada, L8N 4A6
- Investigational Site Number : 1240003
-
-
Quebec
-
Sherbrooke, Quebec, Kanada, J1H 5N4
- Investigational Site Number : 1240004
-
Trois-Rivières, Quebec, Kanada, G8T 7A1
- Investigational Site Number : 1240001
-
-
-
-
Seoul-teukbyeolsi
-
Seoul, Seoul-teukbyeolsi, Korea Południowa, 03722
- Investigational Site Number : 4100001
-
Seoul, Seoul-teukbyeolsi, Korea Południowa, 03080
- Investigational Site Number : 4100002
-
Seoul, Seoul-teukbyeolsi, Korea Południowa, 05030
- Investigational Site Number : 4100004
-
Seoul, Seoul-teukbyeolsi, Korea Południowa, 05505
- Investigational Site Number : 4100006
-
Seoul, Seoul-teukbyeolsi, Korea Południowa, 06351
- Investigational Site Number : 4100005
-
-
-
-
-
Chihuahua City, Meksyk, 31000
- Investigational Site Number : 4840002
-
Durango, Meksyk, 34000
- Investigational Site Number : 4840003
-
Veracruz, Meksyk, 91900
- Investigational Site Number : 4840008
-
-
Nuevo León
-
Monterrey, Nuevo León, Meksyk, 66465
- Investigational Site Number : 4840004
-
-
Querétaro
-
San Juan del Río, Querétaro, Meksyk, 76800
- Investigational Site Number : 4840005
-
-
Yucatán
-
Mérida, Yucatán, Meksyk, 97070
- Investigational Site Number : 4840007
-
-
-
-
-
Leipzig, Niemcy, 04347
- Investigational Site Number : 2760001
-
Mainz, Niemcy, 55128
- Investigational Site Number : 2760005
-
-
-
-
-
Chęciny, Polska, 26-060
- Investigational Site Number : 6160004
-
-
Greater Poland Voivodeship
-
Poznan, Greater Poland Voivodeship, Polska, 60-693
- Investigational Site Number : 6160001
-
-
-
-
Arizona
-
Chandler, Arizona, Stany Zjednoczone, 85224
- Chandler Clinical Research Trials- Site Number : 8400075
-
Tucson, Arizona, Stany Zjednoczone, 85712
- Tucson Clinical Research Institute- Site Number : 8400085
-
-
Colorado
-
Aurora, Colorado, Stany Zjednoczone, 80014
- Allianz Research Institute - Aurora- Site Number : 8400026
-
Wheat Ridge, Colorado, Stany Zjednoczone, 80033
- Western States Clinical Research- Site Number : 8400014
-
-
Florida
-
Boynton Beach, Florida, Stany Zjednoczone, 33435
- Helix Biomedics- Site Number : 8400114
-
Cutler Bay, Florida, Stany Zjednoczone, 33157
- Beautiful Minds Clinical Research Center- Site Number : 8400049
-
Hialeah, Florida, Stany Zjednoczone, 33010
- Qway Research - Hialeah- Site Number : 8400015
-
Miami, Florida, Stany Zjednoczone, 33184
- High Quality Research- Site Number : 8400039
-
Miami, Florida, Stany Zjednoczone, 33186
- Innovations Biotech- Site Number : 8400040
-
Miami, Florida, Stany Zjednoczone, 33186
- New Access Medical Center- Site Number : 8400043
-
Miami, Florida, Stany Zjednoczone, 33135
- Clintex Research Group - Miami - Southwest 27th Avenue- Site Number : 8400048
-
Miami Lakes, Florida, Stany Zjednoczone, 33014
- Deluxe Health Center- Site Number : 8400045
-
Pembroke Pines, Florida, Stany Zjednoczone, 33025
- Tellabio International Research Services- Site Number : 8400083
-
Pembroke Pines, Florida, Stany Zjednoczone, 33029
- Alfa Medical Research LLC- Site Number : 8400146
-
Pensacola, Florida, Stany Zjednoczone, 32503
- Avanza Medical Research Center- Site Number : 8400135
-
Saint Cloud, Florida, Stany Zjednoczone, 34769
- Ilumina Medical Research- Site Number : 8400095
-
Sarasota, Florida, Stany Zjednoczone, 34239
- Windom Allergy, Asthma and Sinus Specialists- Site Number : 8400019
-
-
Georgia
-
Cordele, Georgia, Stany Zjednoczone, 31015
- Private Practice - Dr. David Kavtaradze- Site Number : 8400081
-
-
Massachusetts
-
Boston, Massachusetts, Stany Zjednoczone, 02115
- Brigham & Women's Hospital- Site Number : 8400034
-
-
Michigan
-
Ann Arbor, Michigan, Stany Zjednoczone, 48109
- University of Michigan Health System - Ann Arbor- Site Number : 8400004
-
-
Missouri
-
St Louis, Missouri, Stany Zjednoczone, 63141
- Midwest Clinical Research Center - St. Louis- Site Number : 8400006
-
-
North Carolina
-
Charlotte, North Carolina, Stany Zjednoczone, 28287
- Tryon Medical Partners - Charlotte - Piedmont Row Drive South- Site Number : 8400029
-
-
Ohio
-
Toledo, Ohio, Stany Zjednoczone, 43617
- Asthma & Allergy Center - Toledo- Site Number : 8400017
-
-
Oklahoma
-
Edmond, Oklahoma, Stany Zjednoczone, 73034
- OK Clinical Research- Site Number : 8400021
-
-
Pennsylvania
-
DuBois, Pennsylvania, Stany Zjednoczone, 15801
- Clinical Research Associates of Central Pennsylvania- Site Number : 8400116
-
Pittsburgh, Pennsylvania, Stany Zjednoczone, 15241
- Allergy & Clinical Immunology Associates Pittsburgh- Site Number : 8400007
-
-
Texas
-
Austin, Texas, Stany Zjednoczone, 78759
- Orion Clinical Research- Site Number : 8400001
-
Boerne, Texas, Stany Zjednoczone, 78006
- South Texas Medical Research Institute - TTS Research- Site Number : 8400010
-
Dallas, Texas, Stany Zjednoczone, 75246
- Baylor University Medical Center- Site Number : 8400002
-
El Paso, Texas, Stany Zjednoczone, 79903
- Western Sky Medical Research- Site Number : 8400023
-
McKinney, Texas, Stany Zjednoczone, 75069
- Metroplex Pulmonary and Sleep Center- Site Number : 8400022
-
-
-
-
-
Taipei, Tajwan, 110
- Investigational Site Number : 1580003
-
-
-
-
-
Bursa, Turcja (Türkiye), 16059
- Investigational Site Number : 7920006
-
Istanbul, Turcja (Türkiye), 34098
- Investigational Site Number : 7920002
-
Istanbul, Turcja (Türkiye), 34854
- Investigational Site Number : 7920003
-
Kayseri, Turcja (Türkiye), 38039
- Investigational Site Number : 7920007
-
Kirikkale, Turcja (Türkiye), 71100
- Investigational Site Number : 7920008
-
Mersin, Turcja (Türkiye), 33070
- Investigational Site Number : 7920001
-
İzmit, Turcja (Türkiye), 41001
- Investigational Site Number : 7920005
-
-
-
-
-
Mosonmagyaróvár, Węgry, 9200
- Investigational Site Number : 3480004
-
-
-
-
Roma
-
Rome, Roma, Włochy, 00168
- Investigational Site Number : 3800010
-
-
-
-
-
Bradford, Zjednoczone Królestwo, BD9 6DA
- Investigational Site Number : 8260008
-
Chertsey, Zjednoczone Królestwo
- Investigational Site Number : 8260005
-
London, Zjednoczone Królestwo, W1G 8HU
- Investigational Site Number : 8260011
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, Zjednoczone Królestwo, CB2 2QQ
- Investigational Site Number : 8260001
-
-
Glasgow City
-
Glasgow, Glasgow City, Zjednoczone Królestwo, G12 0YN
- Investigational Site Number : 8260004
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
-
Participants who completed the treatment period of Study DRI16762 or ACT18301, including the EOT visit, as per protocol
-
Participants with stable background therapy with moderate or high-dose ICS in combination with the following controller medications, as maintained during the respective parent study in which they have participated:
- For Study DRI16762: At least 1 and no more than 2 additional controllers (eg, LABA, LAMA, LTRA, or methylxanthines), with or without oral prednisone
- For Study ACT18301: LABA with or without LTRA
-
Participants who are able and willing to participate in the open-label extension study, and to comply with requested study visits and procedures
-
Contraception for male and female participants during the study intervention period and during 8 weeks following the last administration of study intervention. And:
For female participants:
- incapable of becoming pregnant, or
- not pregnant or breast feeding
- no eggs donation or cryopreserving eggs
For male participants:
-- No sperm donation or cryopreserving sperm
- Capable of giving signed informed consent
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
- Participant who developed a new medical condition or a change in status of an established medical condition or requires a new treatment or medication prior to enrollment that, per Investigator's medical judgement would adversely affect participation of the participant in this study or would require permanent lunsekimig discontinuation, or participants potentially at risk of noncompliance to study procedures
- Participant who was diagnosed with a new pulmonary disease which may impair lung function
- Current smoker or active vaping of any products and/or marijuana smoking
- Prescription drug or substance abuse, including alcohol, considered significant by the Investigator
- History of hypersensitivity or allergy to lunsekimig or to any of the excipients used in the presentation or in preparation for administration of lunsekimig, or other allergy that, in the opinion of the Investigator, contraindicates participation in the study
- Participants who are receiving prohibited concomitant medications
- Participants who, during their participation in the parent study, developed an AE or an SAE deemed related to lunsekimig, which in the opinion of the Investigator could indicate that continued treatment with lunsekimig may present an unreasonable risk for the participant
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Lunsekimig
Participants will receive subcutaneous injection of lunsekimig according to established dosing interval |
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Exposure-adjusted incidence rate of treatment-emergent adverse event (TEAE), including adverse events of special interest (AESI), and serious adverse event (SAE)
Ramy czasowe: From study baseline to week 148
|
Exposure-adjusted incidence rate is defined as the number of patients with at least one specific treatment emergent adverse event in question per 100 patients taking the treatment for 1 year. |
From study baseline to week 148
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Annualized rate of asthma exacerbation events
Ramy czasowe: From study baseline to weeks 48, 96 and 144
|
From study baseline to weeks 48, 96 and 144
|
|
|
Change from parent study baseline in pre-bronchodilator (BD) forced expiratory volume in 1 second (FEV1)
Ramy czasowe: From parent study baseline to weeks 48, 96 and 144
|
From parent study baseline to weeks 48, 96 and 144
|
|
|
Serum lunsekimig concentrations
Ramy czasowe: From study baseline to week 144
|
From study baseline to week 144
|
|
|
Incidence and titer of anti-drug antibodies (ADA) against lunsekimig
Ramy czasowe: From study baseline to week 144
|
From study baseline to week 144
|
|
|
Change from parent study baseline in Asthma Control Questionnaire5 (ACQ-5) score
Ramy czasowe: From parent study baseline to weeks 48, 96 and 144
|
The ACQ-5 is a questionnaire that measures the adequacy of asthma control and any changes in asthma control that may occur spontaneously or as a result of treatment. The ACQ-5 has five questions on the asthma symptoms and patients are asked to recall how their asthma has been during the previous week and to respond on a 7-point scale for each question (0 = no impairment, 6 = maximum impairment). The ACQ-5 score is the mean of the 5 questions and, therefore, between 0 (totally controlled) and 6 (severely uncontrolled). A high score indicates low asthma control. |
From parent study baseline to weeks 48, 96 and 144
|
|
Proportion of participants with ≥0.5-point reduction in each ACQ-5 score as compared to parent study baseline score
Ramy czasowe: From parent study baseline to weeks 48, 96 and 144
|
Defined as ACQ-5 responder analysis |
From parent study baseline to weeks 48, 96 and 144
|
|
Change from parent study baseline in Asthma Quality of Life Questionnaire Standardized Activites for 12 years and older (AQLQ[S] +12) domain and total scores
Ramy czasowe: From parent study baseline to weeks 48, 96 and 144
|
The AQLQ(S) + 12 was designed as a self-administered patient reported outcome to measure the functional impairments that are most troublesome to adolescents and adults ≥12 years of age as a result of their asthma. The instrument is comprised of 32 items, each rated on a 7-point Likert scales from 1 to 7. Higher scores indicate better quality of life. |
From parent study baseline to weeks 48, 96 and 144
|
Współpracownicy i badacze
Sponsor
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- LTS17231
- 2025-522896-27 (Identyfikator rejestru: CTIS)
- U1111-1303-3645 (Identyfikator rejestru: ICTRP)
- 2025 (Grant/umowa NIH USA)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .